Aryan Sarparast, Chris Stauffer, Kelan Thomas and Benjamin Malcolm

If MDMA or psilocybin is approved by the FDA for treatment of PTSD and depression, then what will happen to individuals prescribed common psychiatric medications like antidepressants, antipsychotics, and mood stabilizers? This was the question that led to our review, which looked at how psychiatric medications may interact with MDMA or psilocybin. We felt this was important to understand the efficacy and safety of various medication combinations, but also to encourage future clinical trials to investigate drug-drug interactions. Currently, most psychedelic clinical trials require discontinuation of psychiatric medications, which may pose unique risks, like acute psychiatric decline and medication discontinuation syndrome symptoms… continue reading.

Comments are closed.